AU2002339230A1 - A susceptibility gene for late-onset idiopathic parkinson's disease - Google Patents

A susceptibility gene for late-onset idiopathic parkinson's disease

Info

Publication number
AU2002339230A1
AU2002339230A1 AU2002339230A AU2002339230A AU2002339230A1 AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1 AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1
Authority
AU
Australia
Prior art keywords
late
disease
susceptibility gene
idiopathic parkinson
onset idiopathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339230A
Inventor
Andrew A. Hicks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of AU2002339230A1 publication Critical patent/AU2002339230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AU2002339230A 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease Abandoned AU2002339230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36322002P 2002-03-08 2002-03-08
US60/363,220 2002-03-08
PCT/IB2002/004276 WO2003076658A2 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Publications (1)

Publication Number Publication Date
AU2002339230A1 true AU2002339230A1 (en) 2003-09-22

Family

ID=27805269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339230A Abandoned AU2002339230A1 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Country Status (2)

Country Link
AU (1) AU2002339230A1 (en)
WO (1) WO2003076658A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease
DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
CN103278641A (en) * 2005-10-21 2013-09-04 株式会社芳珂 Atopic dermatitis marker and technique of using the same
EP3255049A1 (en) 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN108137586B (en) 2015-09-14 2021-04-13 辉瑞大药厂 Novel imidazo [4,5-c ] quinoline and imidazo [4,5-c ] [1,5] naphthyridine derivatives as LRRK2 inhibitors
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
PE20240221A1 (en) 2016-06-16 2024-02-16 Denali Therapeutics Inc PIRIMIDIN-2-YLAMINO-1H-PYRAZOLES AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072777A2 (en) * 2000-03-13 2001-10-04 Incyte Genomics, Inc. Human transcription factors
US20040248092A1 (en) * 2000-05-26 2004-12-09 Vance Jeffrey M Methods of screening for parkinsons's disease

Also Published As

Publication number Publication date
WO2003076658A2 (en) 2003-09-18
WO2003076658A3 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
GB0318428D0 (en) Gene drivers
EP1580270A4 (en) Gene for increasing crop yield and use thereof
AU2002339230A1 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
AU2002319717A1 (en) Mutant nurr1 gene in parkinson's disease
AU2003272608A1 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
AU2003285346A1 (en) Regulatory elements in the 5' region of the vr1 gene
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003264845A1 (en) Parkinson's disease susceptibility haplotype as a tool for genetic screening
AU2003285069A8 (en) Type 2 diabetes mellitus genes
AU2003257651A1 (en) 4'-thionucleotide
AU2002341044A1 (en) Methods for detecting parkinson's disease
AU2003251962A1 (en) Screening for alzheimer's disease
AU2003268519A1 (en) Type 2 diabetes susceptibility genes
AU2003294705A8 (en) Ntsm gene
GB0410101D0 (en) Parkinson's disease
AU2003284640A1 (en) Type 2 diabetes-associated gene
AU2003211483A1 (en) 4'-c-cyano-2'-deoxypurine nucleosides
AUPS037102A0 (en) A novel gene
PL356071A1 (en) Mutbar 1 gene
EP1514924A4 (en) Novel acylase gene
AU2003252991A1 (en) INTERFERON-Alpha INDUCED GENE
AU2003292404A1 (en) Genetic susceptibility
AU2003905331A0 (en) Bowlers "mate"
AU2001225342A1 (en) Susceptibility gene for autoimmune disease
AU2003285989A1 (en) Mutations in gaba-b receptor 1 associated with epilepsy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase